Selected research
Industry Research
Sexually Transmitted Diseases (STDs) Drug Industry Research Report 2026
Market perspective
The global Sexually Transmitted Diseases (STDs) Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Sexually Transmitted Diseases (STDs) Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Sexually Transmitted Diseases (STDs) Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Sexually Transmitted Diseases (STDs) Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Sexually Transmitted Diseases (STDs) Drug include Bayer Healthcare, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline Plc, Hoffmann La Roche, AbbVie, Inc., Pfizer, Eli Lilly and Merck & Co., Inc., among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Sexually Transmitted Diseases (STDs) Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Sexually Transmitted Diseases (STDs) Drug Market by Company
Bayer Healthcare
Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline Plc
Hoffmann La Roche
AbbVie, Inc.
Pfizer
Eli Lilly
Merck & Co., Inc.
Johnson & Johnson
Sexually Transmitted Diseases (STDs) Drug Segment by Type
Chlamydia
Genital herpes
HPV
Syphilis
Gonorrhea
HIV / AIDS
Sexually Transmitted Diseases (STDs) Drug Segment by Application
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Sexually Transmitted Diseases (STDs) Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sexually Transmitted Diseases (STDs) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sexually Transmitted Diseases (STDs) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sexually Transmitted Diseases (STDs) Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Sexually Transmitted Diseases (STDs) Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Sexually Transmitted Diseases (STDs) Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Sexually Transmitted Diseases (STDs) Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Chlamydia
- Genital herpes
- HPV
- Syphilis
- Gonorrhea
- HIV / AIDS
Applications
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
Companies covered
- Bayer Healthcare
- Bristol-Myers Squibb
- Gilead Sciences
- GlaxoSmithKline Plc
- Hoffmann La Roche
- AbbVie, Inc.
- Pfizer
- Eli Lilly
- Merck & Co., Inc.
- Johnson & Johnson
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Sexually Transmitted Diseases (STDs) Drug Market Size (2021-2032)
- 2.2.2 Global Sexually Transmitted Diseases (STDs) Drug Sales (2021-2032)
- 2.2.3 Global Sexually Transmitted Diseases (STDs) Drug Market Average Price (2021-2032)
- 2.3 Sexually Transmitted Diseases (STDs) Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Chlamydia
- 2.3.3 Genital herpes
- 2.3.4 HPV
- 2.3.5 Syphilis
- 2.3.6 Gonorrhea
- 2.3.7 HIV / AIDS
- 2.4 Sexually Transmitted Diseases (STDs) Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital Pharmacies
- 2.4.3 Online Pharmacies
- 2.4.4 Retail Pharmacies
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Sexually Transmitted Diseases (STDs) Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Sexually Transmitted Diseases (STDs) Drug Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Sexually Transmitted Diseases (STDs) Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Sexually Transmitted Diseases (STDs) Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Sexually Transmitted Diseases (STDs) Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Sexually Transmitted Diseases (STDs) Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Sexually Transmitted Diseases (STDs) Drug, Product Type & Application
- 3.8 Global Manufacturers of Sexually Transmitted Diseases (STDs) Drug, Established Date
- 3.9 Global Sexually Transmitted Diseases (STDs) Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Bayer Healthcare
- 4.1.1 Bayer Healthcare Company Information
- 4.1.2 Bayer Healthcare Business Overview
- 4.1.3 Bayer Healthcare Sexually Transmitted Diseases (STDs) Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Bayer Healthcare Sexually Transmitted Diseases (STDs) Drug Product Portfolio
- 4.1.5 Bayer Healthcare Recent Developments
- 4.2 Bristol-Myers Squibb
- 4.2.1 Bristol-Myers Squibb Company Information
- 4.2.2 Bristol-Myers Squibb Business Overview
- 4.2.3 Bristol-Myers Squibb Sexually Transmitted Diseases (STDs) Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Bristol-Myers Squibb Sexually Transmitted Diseases (STDs) Drug Product Portfolio
- 4.2.5 Bristol-Myers Squibb Recent Developments
- 4.3 Gilead Sciences
- 4.3.1 Gilead Sciences Company Information
- 4.3.2 Gilead Sciences Business Overview
- 4.3.3 Gilead Sciences Sexually Transmitted Diseases (STDs) Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Gilead Sciences Sexually Transmitted Diseases (STDs) Drug Product Portfolio
- 4.3.5 Gilead Sciences Recent Developments
- 4.4 GlaxoSmithKline Plc
- 4.4.1 GlaxoSmithKline Plc Company Information
- 4.4.2 GlaxoSmithKline Plc Business Overview
- 4.4.3 GlaxoSmithKline Plc Sexually Transmitted Diseases (STDs) Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 GlaxoSmithKline Plc Sexually Transmitted Diseases (STDs) Drug Product Portfolio
- 4.4.5 GlaxoSmithKline Plc Recent Developments
- 4.5 Hoffmann La Roche
- 4.5.1 Hoffmann La Roche Company Information
- 4.5.2 Hoffmann La Roche Business Overview
- 4.5.3 Hoffmann La Roche Sexually Transmitted Diseases (STDs) Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Hoffmann La Roche Sexually Transmitted Diseases (STDs) Drug Product Portfolio
- 4.5.5 Hoffmann La Roche Recent Developments
- 4.6 AbbVie, Inc.
- 4.6.1 AbbVie, Inc. Company Information
- 4.6.2 AbbVie, Inc. Business Overview
- 4.6.3 AbbVie, Inc. Sexually Transmitted Diseases (STDs) Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 AbbVie, Inc. Sexually Transmitted Diseases (STDs) Drug Product Portfolio
- 4.6.5 AbbVie, Inc. Recent Developments
- 4.7 Pfizer
- 4.7.1 Pfizer Company Information
- 4.7.2 Pfizer Business Overview
- 4.7.3 Pfizer Sexually Transmitted Diseases (STDs) Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Pfizer Sexually Transmitted Diseases (STDs) Drug Product Portfolio
- 4.7.5 Pfizer Recent Developments
- 4.8 Eli Lilly
- 4.8.1 Eli Lilly Company Information
- 4.8.2 Eli Lilly Business Overview
- 4.8.3 Eli Lilly Sexually Transmitted Diseases (STDs) Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Eli Lilly Sexually Transmitted Diseases (STDs) Drug Product Portfolio
- 4.8.5 Eli Lilly Recent Developments
- 4.9 Merck & Co., Inc.
- 4.9.1 Merck & Co., Inc. Company Information
- 4.9.2 Merck & Co., Inc. Business Overview
- 4.9.3 Merck & Co., Inc. Sexually Transmitted Diseases (STDs) Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Merck & Co., Inc. Sexually Transmitted Diseases (STDs) Drug Product Portfolio
- 4.9.5 Merck & Co., Inc. Recent Developments
- 4.10 Johnson & Johnson
- 4.10.1 Johnson & Johnson Company Information
- 4.10.2 Johnson & Johnson Business Overview
- 4.10.3 Johnson & Johnson Sexually Transmitted Diseases (STDs) Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Johnson & Johnson Sexually Transmitted Diseases (STDs) Drug Product Portfolio
- 4.10.5 Johnson & Johnson Recent Developments
5 Global Sexually Transmitted Diseases (STDs) Drug Market Scenario by Region
- 5.1 Global Sexually Transmitted Diseases (STDs) Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Sexually Transmitted Diseases (STDs) Drug Sales by Region: 2021-2032
- 5.2.1 Global Sexually Transmitted Diseases (STDs) Drug Sales by Region: 2021-2026
- 5.2.2 Global Sexually Transmitted Diseases (STDs) Drug Sales by Region: 2027-2032
- 5.3 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Region: 2021-2032
- 5.3.1 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Region: 2021-2026
- 5.3.2 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Region: 2027-2032
- 5.4 North America Sexually Transmitted Diseases (STDs) Drug Market Facts & Figures by Country
- 5.4.1 North America Sexually Transmitted Diseases (STDs) Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021-2032)
- 5.4.3 North America Sexually Transmitted Diseases (STDs) Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Sexually Transmitted Diseases (STDs) Drug Market Facts & Figures by Country
- 5.5.1 Europe Sexually Transmitted Diseases (STDs) Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021-2032)
- 5.5.3 Europe Sexually Transmitted Diseases (STDs) Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Sexually Transmitted Diseases (STDs) Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Sexually Transmitted Diseases (STDs) Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Sexually Transmitted Diseases (STDs) Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Sexually Transmitted Diseases (STDs) Drug Market Facts & Figures by Country
- 5.7.1 South America Sexually Transmitted Diseases (STDs) Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021-2032)
- 5.7.3 South America Sexually Transmitted Diseases (STDs) Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Sexually Transmitted Diseases (STDs) Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Sexually Transmitted Diseases (STDs) Drug Sales by Type (2021-2032)
- 6.1.1 Global Sexually Transmitted Diseases (STDs) Drug Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Type (2021-2032)
- 6.2.1 Global Sexually Transmitted Diseases (STDs) Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Sexually Transmitted Diseases (STDs) Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Sexually Transmitted Diseases (STDs) Drug Sales by Application (2021-2032)
- 7.1.1 Global Sexually Transmitted Diseases (STDs) Drug Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Sexually Transmitted Diseases (STDs) Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Sexually Transmitted Diseases (STDs) Drug Revenue by Application (2021-2032)
- 7.2.1 Global Sexually Transmitted Diseases (STDs) Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Sexually Transmitted Diseases (STDs) Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Sexually Transmitted Diseases (STDs) Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Sexually Transmitted Diseases (STDs) Drug Value Chain Analysis
- 8.1.1 Sexually Transmitted Diseases (STDs) Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Sexually Transmitted Diseases (STDs) Drug Production Mode & Process
- 8.2 Sexually Transmitted Diseases (STDs) Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Sexually Transmitted Diseases (STDs) Drug Distributors
- 8.2.3 Sexually Transmitted Diseases (STDs) Drug Customers
9 Global Sexually Transmitted Diseases (STDs) Drug Analyzing Market Dynamics
- 9.1 Sexually Transmitted Diseases (STDs) Drug Industry Trends
- 9.2 Sexually Transmitted Diseases (STDs) Drug Industry Drivers
- 9.3 Sexually Transmitted Diseases (STDs) Drug Industry Opportunities and Challenges
- 9.4 Sexually Transmitted Diseases (STDs) Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst